Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




NanoString Technologies to Accelerate Commercialization of Expression Profiling Products

By LabMedica International staff writers
Posted on 15 Jun 2009
NanoString Technologies (Seattle, WA, USA) will receive US$30 million equity financing, which will allow the company to accelerate commercialization of the nCounter analysis system for diagnostics and research. More...


The financing was lead by Clarus Ventures (Cambridge, MA, USA), a global life-sciences venture capital firm and joined by existing investors OVP Venture Partners (Seattle, WA, USA) and Draper Fisher Jurvetson (DFJ; Menlo Park, CA, USA).

The fully automated nCounter analysis system uses digital technology that enables direct multiplexed measurement of gene expression. It is sensitive and precise, and includes detection of fractional fold change differences. The technology uses molecular barcodes and single molecule imaging to detect and count hundreds of transcripts in a single reaction.

"The new funds will fuel our growth in manufacturing and product development and enhance our commercialization capabilities,” said Wayne Burns, CFO and acting CEO of NanoString Technologies.

NanoString Technologies is a life sciences tool company that has developed technology for creating molecular barcodes for tagging individual molecules in a biologic sample.

Related Links:
NanoString Technologies
Clarus Ventures
OVP Venture Partners
Draper Fisher Jurvetson



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.